Novalis LifeSciences Investments I, L.P.
Director, Footnote #1 (See Remarks) at DNA; Stockholder (1) see Remarks at Cerevel Therapeutics Holdings, Inc.
- Sold, on record
- None
- Dollars the filings state
- Form 4 sales
- 0
- None on record
- Form 144 notices
- 2
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- DNAGinkgo Bioworks Holdings, Inc.Director, Footnote #1 (See Remarks)
- Cerevel Therapeutics Holdings, Inc.Stockholder (1) see Remarks
Sales by reason
No Form 4 sale on record for Novalis LifeSciences Investments I, L.P..
Timeline
- 1 Form 144 notice Cerevel Therapeutics Holdings, Inc.NoticeJun 15, 2023 2023
Filed to sell 200,000 shares ($6.9M)
Novalis LifeSciences Investments I, L.P., Stockholder (1) see Remarks
No 10b5-1 planFirst sale on recordFiling
- 2 Form 144 notice DNANoticeMay 16, 2024 +336 days
Filed to sell 265,000 shares ($220k)
Novalis LifeSciences Investments I, L.P., Director, Footnote #1 (See Remarks)
No 10b5-1 planFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (2)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2024 | May 16, 2024 | DNA | Director, Footnote #1 (See Remarks) | Form 144 notice | 265,000 | $220k | Notice | SEC | |
| Jun 15, 2023 | Jun 15, 2023 | Cerevel Therapeutics Holdings, Inc. | Stockholder (1) see Remarks | Form 144 notice | 200,000 | $6.9M | Notice | SEC |